The Impact of the Indonesian Chronic Disease Management Program (PROLANIS) on Metabolic Control and Renal Function of Type 2 Diabetes Mellitus Patients in Primary Care Setting

Abstract

Background: Indonesia through its government National Health Insurance System has launched a non-communicable and chronic disease management program named Indonesian Chronic Disease Management Program (PROLANIS), with Type 2 Diabetes Mellitus (T2DM) and hypertension as the main focus. However, study that evaluates the clinical impact of PROLANIS in patients with T2DM is still scarce to this date. This study aims to evaluate the metabolic control and renal function of PROLANIS participants with T2DM every six month within the first 18-months of implementation. Methods: This study was a retrospective cohort study conducted at Wates sub-district, East Java using secondary data from PROLANIS group report from April 2018 to October 2019. The study population was T2DM patients who voluntarily joined the PROLANIS group in April 2018. The six-month-evaluation included metabolic parameters [body mass index (BMI), blood pressure, hemoglobin A1C, total cholesterol, high-density lipid, low-density lipid, and triglyceride (TG)] and renal parameters [blood urea nitrogen (BUN), creatinine serum, and urinary microalbumin]. Paired t-test and wilcoxon signed-rank test was used for the analysis, and the P-value was adjusted using Bonferroni correction. A P-value < .0015 was considered statistically significant, while a P-value between .0015 and .003 was considered as marginally significant. Results: A total of 30 participants were included in the analysis. Following the PROLANIS implementation, the only parameter of metabolic control that showed significant improvement was TG serum level ( P < .001). Despite the worsening status of other metabolic parameters, the changes were not statistically significant except for BMI that was marginally significant ( P = .002). From renal function, only BUN serum level was significantly deteriorated ( P < .001), while the others did not significantly change. Conclusion: PROLANIS implementation in our study population seems to be ineffective. Future study with more primary healthcare centers needs to be done to scrutinize the clinical impact of this program nationwide.

Kepuasan Peserta Program Pengelolaan Penyakit Kronis (Prolanis) Di Puskesmas Ngesrep Kota Semarang: Preliminary Study

“…Penyakit hipertensi dan DM merupakan penyakit yang tidak dapat disembuhkan, tetapi dapat dikontrol dengan pengobatan dan perubahan gaya hidup. 7 Terapi hipertensi dan DM perlu dilakukan secara berkelanjutan sehingga pasien harus rutin mengkonsumsi obat untuk mengontrol penyakitnya.…”

“…Selain itu terdapat pemeriksaan laboratorium (HbA1C, mikroalbumin, urea, kreatinin, LDL, HDL,dan kolesterol total) setiap 6 bulan, mendapatkan informasi tambahan terkait kesehatan dan perubahan pola hidup yang menunjang kesehatan peserta, mendapatkan pengobatan melalui terapi farmakologi selama satu bulan penuh, dan menambah relasi dengan peserta lain untuk memotivasi diri sehingga semangat dalam menjalankan pengobatan. 7 Puskesmas Ngesrep merupakan Puskesmas yang ada di kota Semarang sejak tahun 1972.…”

Insulin Therapy in T2dm Patients in Diabetes Outpatient Clinic, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

“…Type 2 Diabetes Mellitus (T2DM) is considered as a major health problem, that has a big effect on people's lives and health care costs, with a prevalence of 9% on all adults in the world (Alkaff, et al 2021;Khan, et al, 2019). The high prevalence makes T2DM as the 7 th most cause of death in the world.…”

Acceptance of e‐health technology among older people: A qualitative study

“…Since 2010, BPJS Kesehatan has initiated the Chronic Disease Management Program or Program Pengelolaan Penyakit Kronis (Prolanis), which aims to provide proactive health care for patients with chronic diseases, including hypertension and type 2 diabetes mellitus as the main focus (Alkaff et al, 2021; Khoe et al, 2020; Yusransyah & Suwantika, 2020).…”